Adjunctive cannabidiol in acute bipolar depression: pilot study

Introduction and clinical context

The study Adjunctive cannabidiol in acute bipolar depression: pilot study (Can J Psychiatry · 2023) is part of the scientific research on the use of cannabinoids in depression and mood.

In the field of mood disorders, cannabidiol (CBD) is investigated mainly for its anxiolytic effect, with possible repercussions on associated depressive symptoms. Trials in mild to moderate anxiety reported benefit, while studies in bipolar depression are still pilot and with preliminary results. The evidence for depression is less robust than for anxiety, and psychiatric management remains central.

Understanding what science shows about the use of cannabinoids in depression and mood helps patients and healthcare professionals make safer, well-founded decisions, based on evidence rather than common sense.

Methodology and findings

This clinical trial was conducted in a controlled manner, comparing the treatment with a reference group. Pilot study: adjunctive CBD in bipolar depression (negative primary outcome; suggests studying doses ≥300 mg/day). The blinded, controlled design reduces bias and increases the reliability of the finding. Results from controlled trials like this are especially valuable for guiding therapeutic decisions.

Mechanism of action and safety

In mood disorders, CBD is investigated mainly for its anxiolytic effect, mediated by the modulation of serotonergic receptors (5-HT1A) and of the endocannabinoid system, with a possible repercussion on associated depressive symptoms. Regarding safety, CBD is usually well tolerated, but attention is given to drug interactions and to use in bipolar disorder, where destabilizing mood should be avoided. High doses of THC can worsen anxiety. The cannabinoid is studied as a possible adjuvant, and psychiatric management remains central, with follow-up.

Regulation in Brazil (Anvisa)

In Brazil, access to cannabis products is regulated by Anvisa — mainly through RDC 660/2022 (patient import with a medical prescription) and the new manufacturing and import framework, RDC 1,015/2026. Any therapeutic use must start from an individualized medical assessment and prescription. This content is informative and scientific and does not replace the guidance of a healthcare professional.

This is informative content produced by Brazcann; for the full methodology and detailed results, consult the original publication (Can J Psychiatry · 2023). Access to cannabis treatments must always occur through the regulated pathway, with a prescription and medical follow-up.

Frequently asked questions

Does CBD treat depression?

The evidence is less robust than for anxiety (bipolar studies are pilot); psychiatric management is central.

Does CBD help with associated anxiety?

Trials in mild to moderate anxiety reported benefit, with repercussions on associated symptoms.